16
Participants
Start Date
September 30, 2008
Primary Completion Date
April 30, 2011
Study Completion Date
July 31, 2014
PF-00299804
PF-00299804: Patients take oral 45 mg PF-00299804 once daily starting on Cycle 1 Day 1 until disease progression or unacceptable toxicities occur. One cycle equals 21 days. Dextromethorphan: Patient take a single 30 mg oral dose of dextromethorphan HBr three days prior to Cycle 1 Day 1, and then on Cycle 2 Day 7.
Roswell Park Cancer Institute, Buffalo
South Texas Accelerated Research Therapeutics, LLC, San Antonio
Lead Sponsor
Roswell Park Cancer Institute
OTHER
South Texas Accelerated Research Therapeutics (START)
UNKNOWN
Pfizer
INDUSTRY